Last reviewed · How we verify
NCT05717439
Feasibility and ML Training Investigation of the Senseye DT for Diagnosis of Adults with PTSD
trial testing CAPS-5-R in PTSD in 338 participants. Completed in 25 July 2024.
25 July 2024
Quick facts
| Lead sponsor | Senseye, Inc. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 338 |
| Start date | 1 March 2023 |
| Primary completion | 25 July 2024 |
| Estimated completion | 25 July 2024 |
| Sites | 5 locations across United States |
Drugs / interventions tested
- CAPS-5-R
- Senseye DT
Conditions studied
- PTSD — all drugs for PTSD →
- Generalized Anxiety Disorder — all drugs for Generalized Anxiety Disorder →
- Major Depressive Disorder — all drugs for Major Depressive Disorder →
Sponsor
Senseye, Inc. — full company profile →
Who can join
18 and older, any sex, with PTSD or Generalized Anxiety Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to obtain data on the feasibility of the Senseye Diagnostic Tool (DT) to assess the presence and severity of post-traumatic stress disorder (PTSD) symptoms. The study will also collect data on Generalized Anxiety Disorder (GAD) and Major Depressive Disorder (MDD) to aid in assessing the presence and severity of these disorders both for the purpose of discerning them from PTSD and determining the feasibility of diagnosing them independently.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05717439
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for PTSD
Currently open trials in the same condition.
- NCT07473505 — Integrative Bilateral Cervical Sympathetic Blocks for Trauma-Related Symptoms in Special Operations Veterans: A Prospect · recruiting
- NCT07010757 — Testing an Integrated PTSD and Weight Management Intervention: A Hybrid Type 1 Trial · NA · recruiting
- NCT07372586 — Behavioral Health Collaborative Care Model in an ICU Recovery Clinic · NA · recruiting
- NCT07390786 — Behavioral Health Collaborative Care Model in Post-ICU Clinic Family Pilot · NA · recruiting
- NCT07469098 — Group vs Individual MDMA-Assisted Therapy for PTSD After the October 7, 2023 Events · Phase 2 · recruiting
Other Senseye, Inc. trials
Trials by the same sponsor.
- NCT05372523 — Senseye's OBCI Diagnostic Tool for PTSD · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05717439 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Senseye, Inc.
- Last refreshed: 11 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05717439.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing